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Significant time-by-treatment interaction was observed 
in the RMD group for stool volume (p = 0.014), increas-
ing 56 % compared to baseline (p < 0.01), while remained 
unchanged in the placebo group. Stool consistency was 
improved only in the RMD group (p < 0.01). No adverse 
effects related to study products were observed.
Conclusions The results show that RMD improved CTT, 
stool volume, stool consistency and some intestinal func-
tions in a healthy population.
Keywords Colonic transit time · Resistant maltodextrin · 
Soluble dietary fibre · Stool volume · Intestinal function
Introduction
Food processing has undoubtedly had a permanent effect 
on Western eating habits and led to an unparalleled reduc-
tion in dietary fibre (DF) consumption [1, 2]. The FAO and 
WHO recommend an adequate intake of total fibre of 38 g 
for men and 25 g for women [3, 4]. According to the Euro-
pean Food Safety Authorization (EFSA), a daily intake 
of 25 g of fibre per day is adequate for normal laxation in 
adults [5]. However, and following FAO/WHO recommen-
dations [3], in the USA, a balanced diet is recommended to 
contain between 25 and 38 g of DF [6], but in reality this 
figure is rarely met as DF consumption is on average only 
40 % of the recommended dietary allowance [7]. The DF 
can be defined from multiple points of view, as reviewed 
by Fuentes-Zaragoza et al. [4]. The Codex Alimentarius 
Commission’s Committee on Nutrition and Foods for Spe-
cial Dietary Uses defined DF as “carbohydrate polymers 
with 10 or more monomeric units, which are not hydro-
lysed by the endogenous enzymes in the small intestine 
of humans” [8], definition that included resistant starch, 
Abstract 
Purpose Increased awareness of the importance of die-
tary fibre has led to increased interest in “functional” fibre 
components like digestion-resistant maltodextrin (RMD). 
This randomized, placebo-controlled, double-blind study 
assessed the effects of RMD in the colonic transit time 
(CTT) and defecation characteristics (frequency, stool vol-
ume and consistency).
Methods Sixty-six healthy adult volunteers (32 men) who 
did not have a daily defecation habit had a 7-day run-in 
period before the 21-day intervention period with RMD or 
placebo. CTT and segmental CTT (SCTT) were assessed 
by a single abdominal X-ray film taken at the end of both 
periods after radiopaque marker ingestion. Defecation 
characteristics and intestinal functions were also assessed, 
which were self-reported by patients. Intragroup compari-
sons were evaluated by Student’s paired t test, Bonferroni 
test and Chi-square test, while time comparisons by analy-
sis of variance (ANOVA) and time-by-treatment interaction 
by repeated-measures ANOVA.
Results Fifty-seven subjects were assessed for CTT (pla-
cebo, n = 28; RMD, n = 29). In the RMD group, the total 
CTT, left SCTT and rectosigmoidal SCTT decreased sig-
nificantly compared to baseline (p < 0.01 each; −13.3, 
−4.7, −8.7 h, respectively). Significant differences 
between groups were observed in total CTT and left SCTT. 
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oligosaccharides and other non-digestible carbohydrates 
[4]. The importance of increasing DF consumption in the 
general population has both health and economic benefits 
as it has been shown to be inversely associated with many 
chronic diseases such as coronary heart disease [9], certain 
cancers [10], diabetes [11] and obesity [12]. Furthermore, a 
fibre deficiency can result in a number of associated diges-
tive and metabolic disorders such as inflammatory bowel 
disease, metabolic syndrome and impeded faecal transit 
time [6, 13, 14]. In order to combat the increasing preva-
lence of these disorders, “functional” fibre components, 
namely non-digestible carbohydrates that have beneficial 
physiological effects in humans, have been added to a wide 
variety of foods. For instance, the intake of a dairy prepa-
ration with a fibre supplement containing 20 g of soluble 
fibre improves chronic constipation [15].
In recent years, an increased awareness of the impor-
tance of DF has led to increased interest in functional DFs 
that are neither hydrolysed nor absorbed in the small intes-
tine and pass into the large intestine [16]. To obtain ben-
eficial health benefits is recommended an intake of 20 g/
day of resistant starch (RS), a source of dietary fibre. The 
principal sources of RS are: whole/partly milled grains, 
seeds, legumes, potatoes, green bananas, high-amylose 
corn, bread and processed foods in which modified starches 
been used. However, its dietary intake can vary consider-
ably between countries. For instance, intakes in the EU 
range from 3 to 6 g/day, in the UK resistant starch intakes 
are estimated to be 2.76 g/day, and in Sweden is estimated 
to be 3.2 g/day (reviewed in [17]). The RS food source var-
ies depending on the RS type (reviewed in [17]). Resist-
ant maltodextrin is obtained from corn starch through heat 
and enzymatic treatment. Thus, this process is comprised 
of a hydrolysis reaction by heat and hydrochloric acid in 
low humidity conditions, hydrolysis reaction with amylase, 
refinement and spray-dried [18, 19]. Digestion-resistant 
maltodextrin (RMD [18, 20, 21]) is a non-viscous soluble 
DF, non-digestible carbohydrate and has been reported to 
have various physiological functions in humans. Intestinal 
regularity is typically influenced by DF, and studies have 
shown that RMD increases stool frequency and volume in 
humans [22]. Furthermore, it has been reported that RMD 
is fermented by the intestinal bacterial flora, including bifi-
dobacteria, resulting in an increase in the types and number 
of bacteria in the intestinal flora [20, 23–27]. Fermenta-
tion by gut bacteria leads to short-chain fatty acid (SCFA) 
production, mainly: acetate, propionate and butyrate. For 
instance, butyrate is one of the SCFA for colonic health due 
to its effects on promoting normal development of colono-
cytes. Moreover, the production of SCFA can also lower 
the luminal pH, which can cause the inhibition of poten-
tially pathogenic bacteria growth [28, 29]. In clinical stud-
ies, RMD supplementation has been shown to be highly 
tolerated. Moreover, RMD has been shown to improve 
metabolic syndrome by reducing visceral fat and improving 
glucose and lipid metabolism in humans [14]. Although the 
effect of RMD to reduce the colonic transit time (CTT) has 
been confirmed in animal model studies, no human study 
has been reported [30].
In this context, the main aim of this study was to assess 
the efficacy of RMD supplementation in reducing the CTT 
in healthy subjects with Western diet, compared to non-
digestion-resistant maltodextrin as placebo. We also evalu-
ated the efficacy in reducing the segmental CTT (SCTT), 
improving defecation characteristics (frequency, stool vol-
ume and consistency) and intestinal functions.
Methods
Participants
Healthy participants aged between 18 and 30 years were 
recruited by advertisements at the Universidad Católica 
San Antonio de Murcia. Participants had a body mass index 
(BMI) of less than 30 kg/m2 and a physical activity of less 
than two times per week. Likewise, they did not have a 
daily defecation habit, history of any digestive disease nor 
gastrointestinal/abdominal surgery. All participants pro-
vided informed consent and understood and fulfilled all the 
procedures and requirements of the study. Subjects with 
diabetes, pregnancy and any other conditions that the inves-
tigator regarded as unfit for the study were excluded.
Design
A randomized, placebo-controlled, double-blind, single-
centre clinical study was performed with two parallel 
groups: placebo (non-digestion-resistant maltodextrin) or 
RMD (Fibersol-2, digestion-resistant maltodextrin, Matsu-
tani Chemical Industry Co., Ltd; [18, 20, 21]) at the Uni-
versidad Católica San Antonio de Murcia, Spain. The study 
protocol and the informed consent form were approved 
by the Independent Ethics Committee of the Universidad 
Católica San Antonio de Murcia. The total study duration 
was 28 days, including a 7-day run-in period before inter-
vention to collect baseline data of participants. This was 
followed by a 21-day intervention period from day 8 to 28 
where the participants consumed one of the allocated study 
products daily. Medications or other treatments that would 
result in a change in colonic transit were not permitted, as 
well as medication or nutritional supplement that interfered 
with the formulation.
Before and after the intervention period, physical exami-
nation, blood sample collection and a questionnaire survey 
of intestinal functions were conducted. Daily defecation 
2391Eur J Nutr (2016) 55:2389–2397 
1 3
habits, defecation frequency, stool volume and consistency, 
and 5-day dietary survey in each period were recorded by 
each subject. Medical history and adverse events (AEs) 
were checked at the end of each period. CTT and SCTT 
were assessed by radiography on days 7 and 28.
Subject randomization was performed using a random 
number generator (www.random.org) that allocated the 
subjects in each group.
Interventions
RMD and placebo had the same appearance (in colour 
and size) and flavour and were provided in a 15-g sachet 
in powder form to be dissolved in water. Subjects were 
instructed to consume one sachet daily with breakfast and 
to maintain their normal diet throughout the study.
Measurements
Colonic transit time
To determine CTT, subjects ingested a capsule containing 
24 radiopaque makers (Colognost®, Iberoinversa Pharma) 
daily for five consecutive days at 24-h intervals. Twenty-
four hours after the final marker ingestion an abdomi-
nal X-ray was performed. To calculate CTT, the time 
between each marker ingestion (Δt), the number of mark-
ers observed on the X-ray (n) and the number of markers 
ingested (N) were used in the following formula [31]: CTT 
(h) = (Δt × n)/N.
X-rays were performed using a high kilovoltage and low 
exposure time technique to ensure that marginalized areas 
of the colon were included in the X-ray field. Two physi-
cians counted the markers independently to minimize inter-
observer variability. Subsequently, total CTT and SCTT 
were calculated for each individual using the average from 
both counts. To segment the colon, the fifth lumbar vertebra 
(L5) served as central point to draw three imaginary lines: 
a central line from the third lumbar vertebra (L3) to L5, a 
right line from the L5 to the right femoral head (RFH) and 
a left line from the L5 to the left ilium (LI). The area above 
the right line (L3L5–RFH) was assigned to the right colon, 
the area above the left line (L3L5–LI) was assigned to the 
left colon, and the area below and between right and left 
line (IL–RFH) was assigned to the rectosigmoidal colon.
Intestinal function endpoints
Defecation frequency was self-reported. Stool consist-
ency was determined by each subject using the Bristol 
Stool Chart, which has a 7-point scale from Type 1 for the 
hardest lumpy stools representing constipation to Type 
7 for the watery stools representing diarrhoea. Ideal stool 
consistency covers scores from 3 to 4. Stool volume was 
recorded by subjective visual estimation according to pre-
defined comparative object. Subjects were trained to com-
pare and to assess their stool volume converting it into a 
ping pong ball. Later, they reported to the UCAM roughly 
the number of ping pong balls they converted. Clinical vari-
ables of intestinal function were assessed according to the 
Rome III Criteria: straining, lumpy or hard stools, sensation 
of incomplete evacuation, sensation of anorectal obstruc-
tion and/or blockage, and manual maneuvers to facilitate 
defecation during at least 25 % of defecations, as well as to 
have fewer than three defecations per week. A higher Rome 
III score correlates with higher functional constipation.
Assessment dietary fibre intake
Dietary fibre intake was assessed using a dietary survey. 
A five-day food record (qualitative and quantitative total 
intake) that was maintained by the subjects was processed 
using Diet source® 3.0 that analysed nutritional variables 
including fibre consumption, energy consumption, macro-
nutrient intake as well as any liquid ingested to ensure that 
there were no changes in any study phase in both groups. 
Subjects were advised that they should not vary their 
dietary habits during the study. Moreover, during marker 
ingestion the subjects visually recorded each meal. It was 
checked and verified that female subjects had the same 
estrogenic conditions and in no period of menstruation in 
the days of ingestion of radiopaque markers and measure-
ment of colonic transit time by abdominal radiography.
Safety
The safety profile of the study products was assessed 
through the record of adverse events (AEs) and assessment 
of biochemical parameters.
Blood samples were taken before and after the interven-
tion to asses liver function (ALT, AST) and renal function 
(urea and creatinine). Subjects were instructed to report 
any of suspicious reactions, which were evaluated by the 
medical staff of the Hospital Virgen de la Vega de Murcia 
as possible AEs.
Statistical analysis
The sample size was calculated in order to achieve the pri-
mary objective, with a confidence level of 95 %, beta error 
of 80 %, and estimated difference and standard deviation 
(SD) for the CTT of 5 h and 8.3, respectively [32]. The 
targeting number required for enrolment was 33 in each 
group.
Results were expressed as mean ± SD. The colonic 
transit time and the colonic segmental transit time were 
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compared using ANCOVA for repeated measurements with 
one intrasubject factor (trial time), one intersubject fac-
tor [digestion-resistant maltodextrin (RMD) consumption, 
with or without consumption] and one covariable (fibre 
consumption). Faecal frequency, stool consistency and 
haematological and biochemical variables were compared 
using ANOVA for repeated measurements with one intrasu-
bject factors (trial time) and one intersubject factor [diges-
tion-resistant maltodextrin (RMD) consumption, with or 
without consumption]. For the comparison within a group, 
Dunnett’ multiple comparison test was used. Clinical vari-
ables of intestinal function (Roma III criterion) were com-
pared using the Chi-square test. All statistical analysis was 
performed using SPSS (version 21.0), and a p value <0.05 
was considered statistically significant.
Results
Baseline data
A total of 73 candidates were assessed for eligibility, and 
67 subjects met the criteria and were randomly allocated 
into two groups. One subject was withdrawn during the 
run-in period before receiving intervention (Fig. 1). Thus, 
a total of 66 subjects were analysed, 33 in each study 
group. The demographic and other baseline characteristics 
of subjects in each group are outlined in Table 1. Briefly, 
the population was 51.5 % female with the mean age of 
21.3 years and the mean BMI 23.0 kg/m2. The two study 
groups were well balanced with respect to demographics 
and baseline characteristics, and no significant difference 
was found in any of the variables between groups. The 
mean daily fibre intake was 10.0 ± 4.6 g in the RMD group 
and 11.5 ± 4.6 g in the placebo group. Overall, no signifi-
cant differences in the diet were observed between groups.
Colonic transit time
Although 66 subjects completed the study, 9 subjects (5 
in placebo and 4 in RMD groups) failed to complete CTT 
determination due to non-compliance. Consequently, data 
from 57 subjects were used to measure CTT and SCTT.
The total CTT, left SCTT and rectosigmoidal SCTT 
were significantly decreased in the RMD group after inter-
vention compared to baseline (p < 0.004, p < 0.008 and 
p < 0.006, respectively), while no decrease was found in the 
placebo group. There are significant differences observed 
between groups regarding the total CTT and left SCTT 
(p < 0.028 and p < 0.001, respectively; Table 2). Placebo 
Fig. 1  Disposition of subjects 
for placebo (maltodextrin) and 
digestion-resistant maltodextrin 
(RMD) groups
Assessed for eligibility 
(n=73)
Excluded (n=6)
• Not meeng inclusion criteria (n=6)
Randomized (n=67)
Placebo group
Allocated to intervenon (n=34)
• Received allocated intervenon (n=33)
• Did not receive allocated intervenon 
(n=1). Gastroenteris. 
RMD group
Allocated to intervenon (n=33)
• Received allocated intervenon (n=33)
Lost to follow-up (n=0) Lost to follow-up (n=0)
Analyzed (n=33) Analyzed (n=33)
ENROLLMENT
ALLOCATION
FOLLOW-UP
ANALYSIS
Table 1  Demographics and baseline characteristics of subjects
RMD digestion-resistant maltodextrin, m metres, kg kilograms, BMI 
body mass index, n number of subjects
a Values expressed as mean ± SD (standard deviation)
Placebo (n = 33) RMD (n = 33) Total (n = 66)
Female, n (%) 17 (51.5) 17 (51.5) 34 (51.5)
Age (years)a 21.5 ± 3.2 21.1 ± 2.4 21.3 ± 2.8
Height (m)a 1.73 ± 0.1 1.72 ± 0.1 1.7 ± 0.1
Weight (kg)a 70.3 ± 14.0 67.5 ± 12.3 69.0 ± 13.1
BMI (kg/m2)a 23.3 ± 3.0 22.7 ± 3.0 23.0 ± 3.0
Smoker, n (%) 10 (30.3) 8 (24.2) 18 (27.3)
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intervention did not yield any decrease for the total CTT 
and SCTT. Additionally, stratified analysis by gender did 
not show differences between placebo and RMD groups for 
CTT and SCTT (data not shown).
Intestinal function endpoints
The defecation frequency, stool volume, stool consist-
ency and the number of Rome III positive criteria between 
the two groups did not differ at baseline. After the inter-
vention period, there were significant increases in def-
ecation frequency in both groups compared to baseline 
(RMD 65.8 %, placebo 56.1 %; p < 0.01 each). By con-
trast, the stool volume evolved differently between two 
groups. There were significant increases found in the 
RMD group at Week 1, 2, and 3 (31, 32, 56 %; p < 0.006, 
p < 0.006, p < 0.0001, respectively) compared to base-
line, while in the placebo group there were no changes 
found during intervention (Table 3). Furthermore, there 
was a significant time-by-treatment interaction observed 
in stool volume (p = 0.014). Based on the Bristol Scale 
Score self-recorded, a significant increase (softer and bet-
ter stool consistency) was observed in the RMD group 
after 3 weeks (21.4 %, p < 0.01) compared to baseline. 
No change was observed in the placebo group for the 
stool consistency. Regarding the total number of Rome III 
positive criteria, there were significant reductions in both 
RMD and placebo groups (p < 0.01 each).
Interestingly, analysis of the individual Rome III criteria 
showed that only after intervention with RMD a significant 
lower number of subjects (compared to baseline) answered 
positively to 3 out of 6 criteria: “straining” (from 63.6 to 
33.3 %; p < 0.025), “sensation of incomplete evacuation” 
(from 51.5 to 27.3 %; p < 0.003) in at least 25 % of defeca-
tions, as well as “fewer than three defecations per week” 
(from 24.2 to 0.0 %; p < 0.013).
Table 2  Change in total, right, 
left and rectosigmoidal colonic 
transit time for each group after 
3-week intervention
Values expressed as mean ± SD (standard deviation)
Δ: change from baseline to week 3
* p < 0.05; ** p < 0.01, intragroup significant difference (Student’s paired t test)
# p < 0.05; ## p < 0.01, intergroup significant differences (ANOVA)
Colonic transit time (h) Treatment Baseline Week 3 Δ
Total colon RMD 53.0 ± 23.9 39.7 ± 22.3** −13.3 ± 21.6#
Placebo 48.4 ± 24.1 48.0 ± 25.0 −0.4 ± 21.4
Right colon RMD 12.3 ± 8.0 12.3 ± 8.7 0.1 ± 9.6
Placebo 12.6 ± 12.8 12.4 ± 9.4 −0.2 ± 10.7
Left colon RMD 14.9 ± 9.9 10.2 ± 8.6** −4.7 ± 8.8##
Placebo 9.4 ± 9.1 12.1 ± 9.5* 2.7 ± 6.5
Rectosigmoidal colon RMD 25.9 ± 18.1 17.2 ± 14.6** −8.7 ± 15.4
Placebo 26.5 ± 13.1 23.6 ± 16.0 −2.9 ± 18.7
Table 3  Change in stool 
volume and stool consistency 
for each group during 3-week 
intervention
Values expressed as mean ± SD (standard deviation
Δ: change from baseline to each time point; n.s.: no significant
* p < 0.05, intragroup significant difference (Bonferroni)
† p for time-by-treatment interaction was assessed by a repeated-measures ANOVA
## p < 0.01, intergroup significant differences (ANOVA)
Baseline Week 1 Week 2 Week 3 p value† time × treatment
Stool volume (cm3/day)
 RMD 53.4 ± 30.1 69.9 ± 27.4* 70.2 ± 27.3* 83.4 ± 26.6* 0.014
 (Δ) (16.6 ± 32.9) (16.8 ± 31.2) (30.0 ± 27.4)##
 Placebo 56.4 ± 20.6 59.4 ± 25.0 64.3 ± 25.1 65.6 ± 23.8
 (Δ) (3.0 ± 21.4) (7.9 ± 24.8) (9.2 ± 20.0)
Stool consistency (score)
 RMD 2.8 ± 1.2 3.0 ± 1.0 3.0 ± 1.2 3.4 ± 1.0* n.s.
 (Δ) (0.3 ± 1.0) (0.3 ± 1.2) (0.6 ± 0.8)
 Placebo 2.8 ± 0.8 3.2 ± 0.8 3.2 ± 0.7 3.2 ± 0.5
 (Δ) (0.4 ± 1.0) (0.4 ± 0.9) (0.4 ± 0.8)
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Safety
During the study, six AEs were recorded (2 in placebo 
and 4 in RMD groups). None of the AEs were related to 
the study products nor classified as serious. These events 
were: ankle sprain, cervical muscle spasm, otitis, fever 
and diarrhoea. There were no clinically relevant changes 
observed in the biochemical parameters by haematological 
examination.
Discussion
This randomized, placebo-controlled, double-blind study 
demonstrated that daily consumption of 15 g of a RMD 
supplementation for 21 days significantly reduces the total 
CTT in healthy subjects. The 25.1 % reduction in the total 
CTT was primarily due to the 31.5 % reduction in the left 
CTT. This reduction is physiologically relevant since the 
total and segmented CTT at baseline was within the values 
previously reported for healthy individuals in other studies 
[33, 34]. Some reports have been shown the gender differ-
ences [35], and others not [36]. There was no gender dif-
ference in this study. The lack of gender-related CTT dif-
ferences can be accounted for by the young age range of 
the healthy participants [34]. Subject’s loss in measurement 
of CTT variable for failure to measurement requirements 
did not affect the outcome since the loss was homogeneous 
in both groups. Additionally, the results presented herein 
are consistent to demonstrate that the intake of RMD pro-
vokes increased stool volume, better stool consistency and 
improvement in the intestinal functions. The consumption 
of daily RMD also demonstrated some more benefits to 
reduce the frequency of straining and sensation of incom-
plete evacuation. These results are consistent with the 
widely reported beneficial effects of DF intake [37, 38].
To our knowledge, there were no reports that confirmed 
a significant reducing effect on CTT in humans with other 
soluble DFs (SDFs) before the current study with RMD. 
For example, using either 15 or 20 g/day of inulin for 
21 days did not influence CTT [39, 40]. Another study 
reported that 8 g/day of fructo-oligosaccharides (FOS) for 
28 day failed in modifying CTT, and a meta-analysis of 
FOS concluded that there is no reducing effect on CTT [41, 
42]. Among other studies of SDF, using 3.4 g/day of pectin 
for 28 days, 6 g/day of pectin for 21 days [43, 44], 15 g/
day of guar gum for 18 days [45], 20 g/day of soluble corn 
fibre for 10 days [46], either 20 or 30 g/day of polydextrose 
for 10 days [46, 47] and 30 g/day of arabinogalactan for 
21 days [48], no changes on CTT have been observed. One 
study with 8 g/day polydextrose in 100 g yogurt product 
reported to show a significant change to shorten CTT after 
21-day administration; however, a significant change was 
also found in the placebo group, indicating that it was an 
effect due to the yoghurt product [49]. The current study 
suggests that even in the same category of SDF, the effect 
on the CTT is different. One of the reasons could be the 
characteristics that each SDF possesses such as ferment-
ability by the intestinal bacteria and/or the presence or 
absence of increasing stool weight.
Faecal matter is transported from the ascending colon 
(right colon) to the descending colon (left colon) by intes-
tinal peristalsis. The peristaltic motion is caused by gastro-
colic reflex that occurs when food enters the stomach and in 
response to physical stimuli by the stool bulk. In addition, 
it has been reported that short-chain fatty acids (SCFAs) 
produced by the intestinal bacteria could also stimulate the 
peristalsis [50]. When ingested orally, about 10 % of RMD 
is digested and absorbed as glucose in the small intestine, 
while remaining 90 % reaches the large intestine. Some 
portion of RMD that reaches the colon is fermented slowly 
by the intestinal bacteria such as bifidobacteria, and the 
portion that escapes from bacterial fermentation is excreted 
with faeces. It has been confirmed that the intake of RMD 
leads fermentation by intestinal bacteria and production of 
SCFA in humans [23, 25]. The ratio between the amount 
fermented and excreted has been reported as approximately 
50–50 although it could vary between individuals [24, 30]. 
The fact that a part of RMD is excreted with the faeces 
leads to an increase in stool volume [51, 52]. Consequently, 
it is considered that the increased amount of stool bulk and 
the production of SCFA stimulate the intestinal peristalsis, 
contributing to the reduction in CTT.
The effect of RMD to reduce the CTT in humans was 
confirmed in the present study, and this effect could deeply 
associate with the characteristics of RMD. A distinctive 
characteristic of RMD is a slow speed of fermentation in 
the large intestine compared to other SDF. According to 
the previous report, the estimated speed of fermentation is 
FOS > guar gum > RMD [53]. Another report showed that 
inulin is faster than guar gum [54]. Therefore, FOS, inulin 
and guar gum are rapidly fermented and consumed in the 
first half of the colon, i.e. ascending colon on the right side, 
before reaching the second half of the colon. On the other 
hand, the slow and stable fermentation of RMD enables it 
to reach the second half of the colon, i.e. descending colon 
on the left side, meaning that it provides a source of fer-
mentable carbohydrate to the more distal part of the large 
intestine. The SCFA produced by fermentation reportedly 
cause spontaneous contraction of colon [50]. Thus, it is 
considered that SCFA produced by RMD in the second half 
of the large intestine would induce the intestinal peristalsis, 
resulting in significant reductions in the left CTT and rec-
tosigmoidal CTT. Consequently, the total CTT is shortened 
significantly. Likewise, there is also the possibility that the 
effect of RMD to increase stool bulk generates a synergistic 
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effect with the effect of producing SCFA, which brought 
out the remarkable result observed after the RMD intake.
One limitation in this study could be self-reporting 
nature for defecation variables. However, it is important 
to note that this limitation could be more relevant in some 
variables than in others. For instance, the effect to increase 
stool weight and volume by the intake of RMD has been 
reported in the multiple human studies that evaluated this 
variable using either the measurement of stool weight 
excreted [55, 56] or the visual scoring method [51, 52]. 
The result by visual evaluation has been reported to have 
a high correlation with the result by weight measurement, 
suggesting that besides of being a simple method, the vis-
ual method is reliable [57]. By contrast, the defecation fre-
quency could have unintentionally been increased by the 
subject in the placebo group, since they knew this study 
assessed intestinal functions. Thus, defecation frequency 
is easily the most evident effect that subjects could expect 
from the intervention and so feeling subconsciously the 
need to have more bowel movements. The aforementioned 
observation explains why defecation frequency in the pla-
cebo group was the only variable that displayed a signifi-
cant change. The strengths of the present study included the 
reliable technique used to assess the primary endpoint. In 
order to obtain accurate CTT in humans, the study method 
is extremely important. Since Hinton et al. [58] introduced 
a method using radiopaque marker, it has become the 
standard to ingest radiopaque markers for CTT evaluation. 
The method, however, requires collection of faecal samples 
for several days to determine by X-ray, and its limitation 
has been pointed out that the determination of CTT based 
on the 80 % recovery in the faeces could cause a margin 
of error. A new method was proposed to perform a single 
abdominal X-ray of subjects after every 24-h consecutive 
ingestion of radiopaque markers, providing a less demand-
ing procedure for subjects to finish by only one visit for 
X-ray test without faecal collection. Additionally, the 
method provides the data of not only CTT but also SCTT 
in the large intestine. In this study, a single X-ray method 
was used based on the method by Bouchoucha et al. to 
minimize radiation exposure and to obtain reliable data of 
CTT and SCTT [19]. As a result, CTT before and after the 
ingestion of placebo was almost the same, suggesting that 
the study to determine CTT was conducted accurately with 
good management of subjects and that the results have high 
reliability.
Although this is the first study for RMD to evaluate the 
efficacy on CTT in Western population, the supplementa-
tion of 15 g/day made up for a gap to fulfil 25 g of DF as 
recommended daily intake for adult in EU and other coun-
tries worldwide. Soluble RMD has physiological benefits 
and advantage as easy-to-use in food applications or as a 
supplement. Dietary supplementation of RMD has the 
possibility to help improving DF deficit in the countries, 
where people tend to consume more processed foods.
Conclusions
The results demonstrate that the supplementation of RMD 
has a beneficial effect in improving colonic transit time, 
stool volume, stool consistency and some clinical intesti-
nal functions (for instance, the straining and sensation of 
incomplete evacuation), in a healthy young Western popu-
lation. Furthermore, RMD supplementation has shown to 
have an adequate safety profile. The results open the possi-
bility for the further research of RMD in patients suffering 
from gastrointestinal disorders in Western populations.
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